Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

IMIKERADERM 50 MG/G CREMA - CIMA-AEMPS Drug Approval Details

Approvals/CIMA-AEMPS/IMIKERADERM 50 MG/G CREMA

Approved

STANDARD

IMIKERADERM 50 MG/G CREMA

Mibe Pharma España S.L.U.🇪🇸 Spanish Agency of Medicines and Medical Devices

Approval Date: Aug 11, 2022
Approval ID: 664789345af1efba
Company: Mibe Pharma España S.L.U.
Type: Standard

Approval Details

Approval Id: 664789345af1efba
Drug Cima Aemps Name: IMIKERADERM 50 MG/G CREMA
Register Number: 88034
Holder Company Name: Mibe Pharma España S.L.U.
Marketing Company Name: Mibe Pharma España S.L.U.
Authorization Date: 2022-08-11
Dosage Form: CREMA
Dose: 5 %
Route Of Administration: USO CUTÁNEO
Prescription Type: Medicamento Sujeto A Prescripción Médica
Commercialized: Yes
Company Name: Mibe Pharma España S.L.U.

Active Ingredients

IMIQUIMOD

50 mg

Approved

Quick Info

Agency

CIMA-AEMPS

Country

🇪🇸

Approval Date

Aug 11, 2022

Approval ID

664789345af1efba

Type

Standard

Back to CIMA-AEMPS Approvals